Serum Metabolomic Analysis Discriminates Pancreatic Cancer from New-Onset Diabetic Mellitus

He Xiangyi,Yuan Yaozong

DOI: https://doi.org/10.14309/00000434-201510001-00013

2015-01-01

The American Journal of Gastroenterology

Abstract:Introduction: Due to lack of effective screening methods and specific tumor marker, most of pancreatic cancer(PC) were diagnosed at later stage with the poorest prognosis among all cancers. It is reported that new-onset diabetic mellitus(DM) is an early symptom of PC, and can be a clue for early detection of PC. To screening PC in new-onset DM may narrow the population and be more efficient. Therefore we compared global metabolites profile of serum from patients with new-onset DM and PC with newonset DM, to find metabolic biomarkers associated with PC and establish screening strategy based on new-onset DM. Methods: Serum global metabolite profiles from patients with new-onset Type 2 Diabetic Mellitus (n = 30, DM was diagnosed less than 2 year) and PC with new-onset Type 2 Diabetic Mellitus (n = 30) were obtained using liquid chromatography-mass spectrometry (LC-MS) methods. Data was analyzed using Principal components analysis, partial least-squares discriminant analysis (PLS-DA), Variable Importance in the Projection(VIP model) by Simca-p software, to select statistically significant metabolites. Results: The metabolomic profile of patients with PC+ new-onset DM was significantly different from that of patients with new-onset DM alone. Phospholipid, fatty acids is the major differentiated metabolites. We identified 6 metabolites with the AUC more than 0.75. They are cis_9_palmitoleic_acid (AUC=.755), Glycocholic_Acid (AUC=.787), keto_myristic_acid (AUC=.775), keto_palmitic_acid (AUC=.885), Taurocholic_acid (AUC=.834), Tauroursodeoxycholic_acid (AUC=.826). Conclusion: The serum metabolome of PC related new-onset DM patients is significantly altered, comparing with those with new-onset DM. The utility of serum metabolite biomarkers are potential screening tools for identifying subjects with PC from new-onset DM patients. However it should be further investigated.